Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
This study has been completed.
Study NCT00001805 Information provided by National Institutes of Health Clinical Center (CC)
First Received: November 3, 1999 Last Updated: March 3, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Neoplasms
Colonic Neoplasms
Lung Neoplasms
Pancreatic Neoplasms
Stomach Neoplasms
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Breast Diseases
Colonic Diseases
Colorectal Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Lung Diseases
Neoplasms by Site
Pancreatic Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Skin Diseases
Stomach Diseases
Thoracic Neoplasms
Interventions listed in this trial
Rituximab
Additional drug interventions recognized in this trial
Immunotoxins
More general drug interventions related to this trial
Antineoplastic Agents
Antirheumatic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content
